North America Attention Deficit Hyperactivity Disorder Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Stimulants, Non-Stimulants, and Others), By Age Group (Children, Adolescents, and Adults) and North America Attention Deficit Hyperactivity Disorder Market Insights, Industry Trend, Forecasts to 2035

North America Attention Deficit Hyperactivity Disorder Market Insights Forecasts to 2035

• The North America Attention Deficit Hyperactivity Disorder Market Size Was Estimated at USD 4.92 Billion in 2025
• The Market Size is Expected to Grow at a CAGR of Around 7.01% from 2026 to 2035
• The North America Attention Deficit Hyperactivity Disorder Market Size is Expected to Reach USD 9.68 Billion by 2035

According to a research report published by Spherical Insights & Consulting, the North America Attention Deficit Hyperactivity Disorder market size is anticipated to reach USD 9.68 billion by 2035, growing at a CAGR of 7.01% from 2026 to 2035. The attention deficit hyperactivity disorder market in North America is driven by the increasing prevalence of ADHD among children and adults, growing awareness regarding mental health disorders, rising diagnosis rates, expanding access to treatment options, and continuous advancements in ADHD therapeutics.

Market Overview

ADHD North America market can be understood as the industry encompassing activities related to the diagnosis, treatment, and management of ADHD, a neurodevelopmental condition that affects individuals with symptoms of consistent patterns of inattention, hyperactivity, and impulsiveness. Activities related to pharmaceutical interventions, behavioral interventions, diagnostic activities, digital therapeutics, telehealth services, and more can be considered part of the ADHD market in North America.

As one of the leading regions when it comes to the prevalence of ADHD diagnoses, North America presents an immense market opportunity in this field. Apart from being characterized by good healthcare services and facilities, this region also benefits from favorable insurance plans. Increasing use of telehealth platforms for diagnosing and treating ADHD in North America will continue to drive market dynamics.

Ongoing research and development initiatives for developing innovative medicines, including non-stimulants, extended-release medicines, and others, have the potential to further fuel the ADHD North America market. Growing investments in research on neurology are likely to offer a wide range of opportunities for players in the market. As per the CDC, in 2022, there were approximately 7 million ADHD-diagnosed children in the United States alone.

Report Coverage

This research report categorizes the market for the North America Attention Deficit Hyperactivity Disorder market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America Attention Deficit Hyperactivity Disorder market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America Attention Deficit Hyperactivity Disorder market.

Driving Factors

The North America market for attention deficit hyperactivity disorder is propelled by the increasing incidence of ADHD in children, teenagers, and adults; increasing awareness about mental health diseases, as well as an increasing availability of cutting-edge technologies for diagnosis and treatments. The rise in telemedicine services, increasing spending on healthcare, positive reimbursement conditions, as well as an increased adoption of behavioral and pharmacologic treatments are also adding to the growth of the market.

Restraining Factors

The market growth is restrained by concerns regarding side effects associated with stimulant medications, stringent regulatory requirements for ADHD drugs, medication shortages, high treatment costs, and the risk of drug misuse. Furthermore, social stigma surrounding mental health disorders and challenges associated with long-term treatment adherence may hinder market growth.

Market Segmentation

The North America Attention Deficit Hyperactivity Disorder market share is classified into drug type, age group.

• The children segment accounted for the largest revenue market share in 2025 and is expected to grow at a significant CAGR during the forecast period. 

The North America attention deficit hyperactivity disorder market is segmented by age group into children, adolescents, and adults. Among these, the children segment dominated the share in 2025 and is anticipated to grow at a remarkable CAGR during the forecast period. The growth is driven by increasing diagnosis rates among school-aged children, growing awareness among parents and educators, improved screening programs, and expanding access to pediatric mental healthcare services. Early intervention initiatives and greater recognition of ADHD symptoms are further contributing to segment expansion.

• The retail pharmacies segment dominated the share in 2025 and is anticipated to grow at a remarkable CAGR during the forecast period. 

The North America attention deficit hyperactivity disorder market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. Among these, the retail pharmacies segment dominated the share in 2025 and is anticipated to grow at a substantial CAGR during the forecast period. This dominance is attributed to extensive pharmacy networks, convenient medication access, high prescription volumes, favorable insurance coverage, and increasing patient reliance on community pharmacy services for chronic disease management and medication refills.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America Attention Deficit Hyperactivity Disorder market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Johnson & Johnson
• Pfizer Inc.
• Supernus Pharmaceuticals, Inc.
• Novartis AG
• Neos Therapeutics, Inc.
• Curemark LLC
• Otsuka Pharmaceutical Co., Ltd.
• Tris Pharma, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments:

• In December 2025, Tris Pharma, Inc. continued expansion of its ADHD treatment portfolio across North America following increased adoption of extended-release formulations.
• In March 2025, leading pharmaceutical companies increased investments in next-generation ADHD therapies and digital treatment solutions aimed at improving patient adherence and long-term outcomes.

Market Segment

This study forecasts revenue at the North America, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the North America Attention Deficit Hyperactivity Disorder market based on the below-mentioned segments:

North America Attention Deficit Hyperactivity Disorder Market, By Drug Type

• Stimulants
• Non-Stimulants
• Others

North America Attention Deficit Hyperactivity Disorder Market, By Age Group

• Children
• Adolescents
• Adults